Precision Events - ASCO 2026

iStock-2256589842

Built for the next era of oncology

Oncology trials today demand more than execution. They require precision at every step. From increasingly complex protocols to biomarker-driven endpoints and global regulatory expectations, the margin for inefficiency is shrinking.

Precision for Medicine brings together clinical execution, biomarker strategy, and biospecimen logistics into one connected model — so you can move faster, reduce risk, and deliver more value to every patient.

Book a meeting

600 trials across phases

77% oncology-focused trials in the last 5 years

2000 translational research programs delivered

Meet our Executive Leadership Team

Margaret Keegan

Chief Executive Officer, Precision Medicine Group
Chad Clark

President and Chief Operating Officer, Precision Medicine Group
Matt Grow

Chief Commercial Officer, Precision for Medicine
Harpreet Singh, MD

Chief Medical Officer, Precision for Medicine
Deborah Phippard, PhD

Chief Scientific Officer, Precision for Medicine
Daisy DeWeese-Gatt, MPH

President, Clinical Solutions
Darren Davis, PhD

Senior Vice President, Translational Sciences, Precision for Medicine
Andrea Cotton-Berry

Global Head of Strategic Development, Precision for Medicine

Institute@Precision

Radiopharmaceuticals: Moving from Innovation to Real-World Delivery

While radiopharmaceuticals are reshaping oncology, their global adoption remains constrained by complex regulatory frameworks, manufacturing limitations, and fragmented supply chains.

This white paper explores the key challenges shaping global access to radiopharmaceuticals and what sponsors must consider as development and commercialization efforts expand worldwide.

Read the full analysis to see how the landscape is evolving and what shapes commercial success.

Download now

Curated Insights from the Frontlines of Oncology Research

Whether you're advancing a first-in-human study, optimizing dose strategy, or scaling a global program, we're here to help you move forward with clarity and confidence.

Talk to an Oncology Expert

Brochure
Guiding the Way for Novel Therapeutics in Complex Indications
Download Brochure
Whitepaper
Beyond Geography: A Former Regulator’s Perspective on Multiregional Oncology Trials
Download Whitepaper
Brochure
Translational and Biomarker Sciences: Enabling Breakthroughs
Download Brochure
eBook
Phase 1 Oncology Clinical Trial Designs
Download eBook

Margaret Keegan

Margaret Keegan

Chief Executive Officer, Precision Medicine Group

Industry luminary, passionate about building tech-enabled and data-driven operational models that streamline development and access for much needed medicines. Former leader at the world’s largest and most successful CROs, as COO at PRA Health Services and President of IQVIA Clinical Development. Expert in the full range of clinical development functions including biostatistics, data, safety, regulatory, clinical development, and sales. Driven to enable leaders and teams to be their best and to deliver with excellence for our clients and the patients we serve.

Chad_Clark_Resize

Chad Clark

President and Chief Operating Officer, Precision Medicine Group

Recognized industry leader with deep expertise spanning biomarker-driven clinical development, patient access and global market access. In addition to the role at Precision Medicine Group, Chad is also President of Precision for Medicine. In prior roles he has served as Chief Operating Officer of United BioSource Corporation and founder of DataPhaseIV. Proven ability to scale operations in response to client needs, adding the end-to-end capabilities necessary to support development and patient access to today’s complex therapies.

Matt Grow 1

Matt Grow

Chief Commercial Officer, Precision for Medicine

Visionary leader with a strong track record of fostering growth through commercial innovation and excellence. Drives sales by evolving the go-to-market model, landing and expanding key customer segments, and strengthening active client relationships. Proven expertise in biotech and pharmaceutical development spanning executive management, strategy, business development, sales, marketing and account management.

Harpreet-Singh2

Harpreet Singh, MD

Chief Medical Officer, Precision for Medicine

Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors.

Deb Phippard

Deborah Phippard, PhD

Chief Scientific Officer, Precision for Medicine

Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.

Daisy-DeWeese-Gatt

Daisy DeWeese-Gatt, MPH

President, Clinical Solutions

Industry veteran with over 25 years’ experience working across all phases of global drug development and leading large international teams, most recently at ICON Biotech and a team of 3,000 people across 45 countries. Passionate about driving breakthroughs in treatment for oncology and rare diseases. Prior roles include senior leadership positions at IQVIA Biotech and PPD. Proven ability to lead operational excellence and deliver results for oncology innovators. Maintains a part-time faculty role at the University of North Carolina Wilmington.

Darren Davis

Darren Davis, PhD

Senior Vice President, Translational Sciences, Precision for Medicine

Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases.

Andrea Cotton

Andrea Cotton-Berry

Global Head of Strategic Development, Precision for Medicine

Notable authority in global operations, dedicated to fostering team spirit of excellence and collaboration with internal and external partners. Veteran of the quest to improve oncology therapies and extend lives, including 15+ years in oncology drug development, building on 10 years in obstetrics and women’s health.